PL2489733T3 - Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego - Google Patents

Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego

Info

Publication number
PL2489733T3
PL2489733T3 PL12152550T PL12152550T PL2489733T3 PL 2489733 T3 PL2489733 T3 PL 2489733T3 PL 12152550 T PL12152550 T PL 12152550T PL 12152550 T PL12152550 T PL 12152550T PL 2489733 T3 PL2489733 T3 PL 2489733T3
Authority
PL
Poland
Prior art keywords
gene therapy
spinal cord
lateral sclerosis
amyotrophic lateral
cord disorders
Prior art date
Application number
PL12152550T
Other languages
English (en)
Inventor
James Dodge
Lamya Shihabuddin
Catherine R. O'riordan
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL2489733T3 publication Critical patent/PL2489733T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
    • C12N15/8645—Adeno-associated virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL12152550T 2006-06-07 2007-06-07 Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego PL2489733T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81141906P 2006-06-07 2006-06-07
PCT/US2007/013391 WO2007146046A2 (en) 2006-06-07 2007-06-07 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
EP12152550.5A EP2489733B1 (en) 2006-06-07 2007-06-07 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
EP07795835.3A EP2029742B1 (en) 2006-06-07 2007-06-07 Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders

Publications (1)

Publication Number Publication Date
PL2489733T3 true PL2489733T3 (pl) 2019-08-30

Family

ID=38832369

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07795835T PL2029742T3 (pl) 2006-06-07 2007-06-07 Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego
PL12152550T PL2489733T3 (pl) 2006-06-07 2007-06-07 Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL07795835T PL2029742T3 (pl) 2006-06-07 2007-06-07 Terapia genowa w stwardnieniu zanikowym bocznym i innych zaburzeniach rdzenia kręgowego

Country Status (19)

Country Link
US (4) US9034836B2 (pl)
EP (3) EP3540054A3 (pl)
JP (6) JP2009539847A (pl)
CN (1) CN101460621B (pl)
AR (2) AR061282A1 (pl)
BR (1) BRPI0711965A2 (pl)
CA (2) CA3139726A1 (pl)
CY (1) CY1118555T1 (pl)
ES (2) ES2725552T3 (pl)
HU (2) HUE044182T2 (pl)
IL (2) IL195647A (pl)
LT (2) LT2489733T (pl)
MX (4) MX364444B (pl)
PL (2) PL2029742T3 (pl)
PT (2) PT2029742T (pl)
RU (1) RU2008152821A (pl)
SI (2) SI2029742T1 (pl)
TR (1) TR201906106T4 (pl)
WO (1) WO2007146046A2 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX364444B (es) 2006-06-07 2019-04-26 Genzyme Corp Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal.
ES2596360T3 (es) * 2008-01-16 2017-01-09 Neurodyn Life Sciences Inc. Progranulina para su uso en el tratamiento de enfermedad de Parkinson o enfermedad de Alzheimer
CN102272321A (zh) 2008-10-31 2011-12-07 神经动力公司 神经毒性甾醇糖苷
EP3988660B1 (en) 2009-05-02 2025-05-14 Genzyme Corporation Gene therapy for neurodegenerative disorders
EP2640407A4 (en) * 2010-11-16 2014-07-09 Denis G Kay PROCESS FOR INCREASING THE EXPRESSION AND ACTIVITY OF NEPRILYSIN
CN103083667A (zh) * 2011-11-01 2013-05-08 北京清美联创干细胞科技有限公司 嗅鞘细胞增殖试剂的连续给药方案
EP2850093B1 (en) 2012-01-27 2019-01-09 The Board of Trustees of the Leland Stanford Junior University Therapeutic il-13 polypeptides
CN104619334A (zh) 2012-08-09 2015-05-13 利兰斯坦福初级大学董事会 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
CN104853778A (zh) 2012-10-24 2015-08-19 第一三共株式会社 用于肌萎缩性侧索硬化的治疗剂
WO2014084085A1 (ja) * 2012-11-28 2014-06-05 国立大学法人名古屋大学 聴覚障害又は小脳性運動失調症の予防・治療剤
AU2013388083B2 (en) * 2013-05-01 2019-08-22 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
RU2018128780A (ru) * 2013-07-26 2018-12-05 Юниверсити Оф Айова Рисерч Фаундейшн Способы и композиции для лечения болезней мозга
KR101548989B1 (ko) 2013-07-30 2015-09-01 광주과학기술원 ＳｉｒＴ１을 이용한 관절 질환의 예방 또는 치료용 물질의 스크리닝 방법
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
KR20170096998A (ko) 2014-11-05 2017-08-25 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 aadc 폴리뉴클레오티드
CA2987103A1 (en) * 2015-05-28 2016-12-01 Cornell University Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
CL2015003024A1 (es) 2015-10-09 2016-05-13 Univ Chile Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrofica.
WO2017087486A1 (en) * 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
JP7436089B2 (ja) * 2016-03-02 2024-02-21 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 前頭側頭型認知症の治療
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
US11827906B2 (en) 2017-02-28 2023-11-28 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clade f vector and uses therefor
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
KR102709597B1 (ko) * 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
IL273776B2 (en) 2017-10-03 2025-06-01 Prevail Therapeutics Inc Gene therapies for lysosomal disorders
AU2018346102B2 (en) 2017-10-03 2023-05-11 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
WO2019073299A1 (en) * 2017-10-10 2019-04-18 Medicenna Therapeutics, Inc. IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
JP2021523914A (ja) 2018-05-15 2021-09-09 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． パーキンソン病を治療するための組成物および方法
WO2019239213A2 (en) 2018-06-01 2019-12-19 Medicenna Therapeutics Inc. Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
RU2731514C2 (ru) * 2018-12-21 2020-09-03 Селл энд Джин Терапи Лтд Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов SHH, CTNNB1, NOG, WNT7A для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-SHH, или Escherichia coli SCS110-AF/VTvaf17-CTNNB1, или Escherichia coli SCS110-AF/VTvaf17-NOG, или Escherichia coli SCS110-AF/VTvaf17-WNT7A, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора
WO2020160458A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
KR20210131370A (ko) 2019-02-22 2021-11-02 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
CA3136004A1 (en) 2019-04-10 2020-10-15 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
CN114430684A (zh) * 2019-04-12 2022-05-03 编码治疗公司 用于治疗剂投予的组成物及方法
US20220235373A1 (en) * 2019-10-12 2022-07-28 Shenzhen University Agent that enables sirt7 gene expression and the use thereof
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
WO2023242844A1 (en) * 2022-06-15 2023-12-21 Ramot At Tel-Aviv University Ltd. Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
CN115323002A (zh) * 2022-07-28 2022-11-11 深圳先进技术研究院 一种基因递送系统在从脑部逆行递送基因到脊髓神经元中的应用
CN120590487A (zh) * 2025-06-17 2025-09-05 河北医科大学第二医院 一种信号肽、重组载体及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8303626D0 (sv) 1983-06-23 1983-06-23 Kabigen Ab A recombinant plasmid a transformant microorganism, a polydoxyrebonucleotide segment, a process for producing a biologically active protein, and the protein thus produced
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
DE69435223D1 (de) 1993-10-25 2009-09-03 Canji Inc Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
JPH09509564A (ja) 1993-11-09 1997-09-30 ターゲテッド ジェネティックス コーポレイション 高力価組換えａａｖベクターの生成
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5882914A (en) 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
AU1525797A (en) 1996-04-22 1997-11-12 Medtronic, Inc. Two-stage angled venous cannula
US20040076613A1 (en) * 2000-11-03 2004-04-22 Nicholas Mazarakis Vector system
CA2311643C (en) 1997-12-04 2009-04-07 Genzyme Corporation Compositions and methods for inducing gene expression
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6468524B1 (en) 2000-03-22 2002-10-22 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services AAV4 vector and uses thereof
US7037493B2 (en) * 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
AU2001268149B2 (en) * 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
CA2423082A1 (en) 2000-09-18 2002-03-28 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
GB0103998D0 (en) * 2001-02-19 2001-04-04 King S College London Method
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
WO2003004660A1 (en) * 2001-07-03 2003-01-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods of administering vectors to synaptically connected neurons
AU2002364221B2 (en) 2001-12-21 2008-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US7576065B2 (en) * 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20060246036A1 (en) * 2002-09-06 2006-11-02 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
JPWO2006035741A1 (ja) 2004-09-29 2008-05-15 伸弥 山中 Ｅｓ細胞特異的発現遺伝子及びその利用
US7951928B2 (en) 2004-11-18 2011-05-31 Tokyo Medical And Dental University Gene encoding a protein and preventive/remedy for neurodegenerative diseases such as polyglutamine diseases by utilizing the same
BRPI0611379A2 (pt) 2005-05-02 2010-08-31 Genzyme Corp terapia genética para distúrbios neurometabólicos
EP1879623B1 (en) * 2005-05-02 2012-10-03 Genzyme Corporation Gene therapy for spinal cord disorders
MX364444B (es) 2006-06-07 2019-04-26 Genzyme Corp Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la médula espinal.
AU2012330885B2 (en) 2011-11-01 2016-10-06 Resverlogix Corp. Oral immediate release formulations for substituted quinazolinones
US20150182637A1 (en) 2012-06-21 2015-07-02 Association Institut De Myologie Widespread gene delivery of gene therapy vectors

Also Published As

Publication number Publication date
MX2008015530A (es) 2009-02-06
PL2029742T3 (pl) 2017-08-31
EP2489733B1 (en) 2019-02-13
IL195647A (en) 2015-10-29
JP2014012697A (ja) 2014-01-23
US20200101138A1 (en) 2020-04-02
EP2029742A4 (en) 2009-09-30
CY1118555T1 (el) 2017-07-12
EP3540054A3 (en) 2019-10-09
JP2020079234A (ja) 2020-05-28
JP2015120719A (ja) 2015-07-02
EP2489733A3 (en) 2012-11-14
TR201906106T4 (tr) 2019-05-21
JP2009539847A (ja) 2009-11-19
US20100267812A1 (en) 2010-10-21
EP2029742A2 (en) 2009-03-04
JP2018118995A (ja) 2018-08-02
SI2029742T1 (sl) 2016-11-30
MX2019004843A (es) 2021-06-15
IL195647A0 (en) 2009-09-01
IL241890A0 (en) 2015-11-30
SI2489733T1 (sl) 2019-06-28
PT2489733T (pt) 2019-05-27
AR109171A2 (es) 2018-11-07
WO2007146046A2 (en) 2007-12-21
CA2654292A1 (en) 2007-12-21
MX2023001965A (es) 2023-02-23
PT2029742T (pt) 2016-09-09
CN101460621B (zh) 2016-01-27
RU2008152821A (ru) 2010-07-20
JP2017078071A (ja) 2017-04-27
US9034836B2 (en) 2015-05-19
LT2489733T (lt) 2019-05-27
EP3540054A2 (en) 2019-09-18
AR061282A1 (es) 2008-08-20
HUE044182T2 (hu) 2019-10-28
CA3139726A1 (en) 2007-12-21
WO2007146046A3 (en) 2008-05-22
MX364444B (es) 2019-04-26
US20230364200A1 (en) 2023-11-16
LT2029742T (lt) 2016-11-10
BRPI0711965A2 (pt) 2012-01-24
CN101460621A (zh) 2009-06-17
US11554161B2 (en) 2023-01-17
ES2725552T3 (es) 2019-09-24
US20160067312A1 (en) 2016-03-10
ES2596885T3 (es) 2017-01-12
HUE031156T2 (en) 2017-06-28
EP2489733A2 (en) 2012-08-22
EP2029742B1 (en) 2016-07-20
CA2654292C (en) 2022-01-11
JP6606215B2 (ja) 2019-11-13
JP6320489B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
PT2489733T (pt) Terapia genética para esclerose lateral amiotrófica e outros distúrbios da medula espinal
PT3146982T (pt) Terapia génica para esclerose lateral amiotrófica e outros distúrbios da medula espinal
IL237658A0 (en) Gene therapy for spinal cord disorders
HRP20182147T8 (hr) Novi terapijski pristupi za liječenje cmt-a i srodnih poremećaja
IL198492A0 (en) Pathotropic targeted gene delivery system for cancer and other disorders
IL197818A0 (en) Multiple sclerosis therapy
PL2147058T3 (pl) Pirogeniczna, silanizowana i zmielona krzemionka
EP2158316A4 (en) GENE EXPRESSION AND PAIN
PL2147059T3 (pl) Pirogeniczna, silanizowana i zmielona krzemionka
PL1993589T3 (pl) Sposoby leczenia chorób neurologicznych
IL193697A0 (en) Methods for treating cognitive and other disorders
EP2099389A4 (en) IMPLANTABLE INTERVERTEBRAL DISC
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
GB0406728D0 (en) Gene therapy
SI1879623T1 (sl) Genska terapija za motnje hrbtenjače
IL255035A0 (en) Gene therapy for spinal cord disorders
GB0618403D0 (en) Treatment of amyotrophic lateral sclerosis
GB0616452D0 (en) Novel therapy for joint disorders
AU2006901311A0 (en) Liver-directed gene therapy
SI1993589T1 (sl) Zdravljenje za nevrološka obolenja